Better biofactories

STAFFORDSHIRE, U.K.—Cobra Biomanufacturing developed a method that provides cleaner biologics
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
STAFFORDSHIRE, U.K.—Increasingly, scientists are using bacteria to produce a variety of products as therapeutics as well as for other applications. Unfortunately, endogenous proteins and metabolic products within the microbes can contaminate and seriously compromise the desired product. With an eye to eliminating the genes that produce these contaminants, scientists at Cobra Biomanufacturing developed a method that offers higher efficiencies than random recombination and does not rely on exogenous recombinases or transposases. They presented their work in Applied and Environmental Microbiology (2006, 72, 2520-2525).
Continue reading below...
3D illustration of immune cells in purple interacting with red cancerous tissue.
WebinarsDecoding immune–tumor interactions with functional genomics
Discover how coculture models and CRISPR tools reveal new insights into tumour microenvironments.
Read More
The researchers relied on Xer recombinases, enzymes that naturally occur in most bacterial strains, to remove ("Xer"-cise) target genes in E. coli and B. subtilis strains, and used PCR to confirm their results. With E. coli, they deleted a gene responsible for adding an immunogenic myristoyl group to lipid A and thereby reduced the endotoxicity of the microbe for plasmid DNA production. Similarly, in B. subtilis, they were able to delete the genes responsible for proteases that degrade secreted recombinant proteins.
The researchers expect that their technique will become more widely applicable as scientists discover more microbes that carry Xer-sensitive recombination sequences and foresee the possible application of this technology in selective gene removal in eukaryotic organisms.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Fluorescent-style illustration of spherical embryonic stem cells clustered together against a dark background.
Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes. 
3D illustration of ciliated cells, with cilia shown in blue.
Ultraprecise proteomic analysis reveals new insights into the molecular machinery of cilia.
3D illustration showing a DNA double helix encapsulated in a transparent capsule, surrounded by abstract white and orange protein-like molecular structures against a blue background.
Discover an integrated analytical approach that unites identification, purification, and stability assessment for therapeutic molecules.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue